Grace Therapeutics, Inc.
GRCE
$2.27
-$0.03-1.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.59M | 1.99M | 1.96M | 2.14M | 1.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.01M | 2.45M | 2.53M | 3.09M | 3.18M |
| Operating Income | -3.01M | -2.45M | -2.53M | -3.09M | -3.18M |
| Income Before Tax | -2.88M | -2.32M | -938.00K | -3.36M | -382.00K |
| Income Tax Expenses | -1.70M | -- | -- | -- | -1.02M |
| Earnings from Continuing Operations | -1.18M | -2.32M | -938.00K | -3.36M | 636.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.18M | -2.32M | -938.00K | -3.36M | 636.00K |
| EBIT | -3.01M | -2.45M | -2.53M | -3.09M | -3.18M |
| EBITDA | -3.01M | -2.45M | -2.53M | -3.09M | -3.18M |
| EPS Basic | -0.07 | -0.14 | -0.06 | -0.21 | 0.05 |
| Normalized Basic EPS | -0.10 | -0.09 | -0.04 | -0.13 | -0.02 |
| EPS Diluted | -0.07 | -0.14 | -0.06 | -0.21 | 0.05 |
| Normalized Diluted EPS | -0.10 | -0.09 | -0.04 | -0.13 | -0.02 |
| Average Basic Shares Outstanding | 17.26M | 16.93M | 15.92M | 15.92M | 13.83M |
| Average Diluted Shares Outstanding | 17.26M | 16.93M | 15.92M | 15.92M | 13.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |